- £2.04bn
- £5.37bn
- £797.20m
- 27
- 42
- 37
- 25
R2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 633 | 637 | 624 | 792 | 797 |
Cost of Revenue | |||||
Gross Profit | 618 | 622 | 606 | 769 | 764 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 379 | 399 | 434 | 571 | 688 |
Operating Profit | 254 | 238 | 190 | 221 | 109 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 201 | 193 | 132 | 128 | -8.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 169 | 123 | 107 | 15.6 | 0.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 223 | 207 | 1,762 | 15.4 | 0.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 214 | 200 | 1,762 | 15.4 | 0.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.549 | 0.434 | 0.414 | -0.217 | 0.009 |
Dividends per Share | |||||
Special Dividends per Share |